Premenopausal women have a lower cardiovascular
|
|
- Katherine Wright
- 5 years ago
- Views:
Transcription
1 AJH 1998;11: Ambulatory Not Office Blood Pressures Decline During Hormone Replacement Therapy in Healthy Postmenopausal Women Frans J. van Ittersum, W. Marchien van Baal, Peter Kenemans, Velja Mijatovic, Ab J.M. Donker, Marius J. van der Mooren, and Coen D.A. Stehouwer Hormone replacement therapy (HRT, estrogen plus progestagen) in postmenopausal women has beneficial effects on the cardiovascular system. However, effects on blood pressure, determined with office measurements, remain controversial. We studied the effects of HRT in 29 healthy normotensive postmenopausal women (mean age 52.3 [3.8] years, median duration of amenorrhea 34.5 months), using ambulatory blood pressure monitoring at baseline and at 3 and 12 months of follow-up. Women were randomized to two groups: an HRT group (N 14), treated with 1 mg 17 -estradiol once daily and 5 or 10 mg dydrogesterone once daily during the third and fourth week of every 4 weeks; and a control group (C-group, N 15), which did not receive therapy. Blood pressures did not differ between the groups at baseline (HRT group (9.2)/74.4 (6.6) mm Hg, C-group (11.2)/71.3 (7.4) mm Hg). During the follow-up period, changes from baseline of Premenopausal women have a lower cardiovascular risk than age-matched men. 1 Menopause is believed to greatly increase the risk for cardiovascular diseases and to remove the advantage over men, as demonstrated in the Framingham Study. 1 A hypothetical explanation of this phenomenon is a postmenopausal lack of estrogen. office blood pressures did not differ significantly between the groups. However, changes (95% CI) of mean 24-h blood pressures differed significantly between the two groups after 1 year of follow-up: a decrease of blood pressures was observed in the HRT group ( systolic/ diastolic 5.54 [ 8.86 to 2.21]/ 4.23 [ 6.66 to 1.80] mm Hg), whereas an increase was found in the C-group ( 3.33 [ 0.69 to 7.35]/ [ 1.75 to 5.09] mm Hg; P [HRT v control group].001/.005). We conclude that HRT may have blood pressure lowering properties in healthy, normotensive postmenopausal women. Am J Hypertens 1998;11: American Journal of Hypertension, Ltd. KEY WORDS: Twenty-four-hour ambulatory blood pressure monitoring, office blood pressures, hormone replacement therapy, postmenopausal women. Metaanalyses of observational studies suggest a 50% reduction in heart disease risk in postmenopausal women taking estrogen replacement therapy (ERT). 2,3 Not only does administration of estradiol in postmenopausal women lead to an increase in HDL-cholesterol and a decrease in LDL-cholesterol, but it also leads to systemic vasodilation, an increase in cardiac Received July 31, Accepted May 19, From the Institute for Cardiovascular Research Vrije Universiteit Amsterdam, Department of Medicine (FJvI, AJMD, CDAS), and Department of Obstetrics and Gynecology, (WMvB, PK, VM, MJvdM) Academisch Ziekenhuis Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Address correspondence and reprint requests to F.J. van Ittersum, MD, Department of Medicine, afdeling 0-Noord, Academisch Ziekenhuis Vrije Universiteit, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; fj.vanittersum@azvu.nl 1998 by the American Journal of Hypertension, Ltd /98/$19.00 Published by Elsevier Science, Inc. PII S (98)
2 1148 VAN ITTERSUM ET AL AJH OCTOBER 1998 VOL. 11, NO. 10, PART 1 output and reversal of the decreased arterial compliance, 4 6 as well as to an enhancement of systemic fibrinolysis. 7 Observational studies indicate that hormone replacement therapy (estrogen plus progestagen, HRT) may be as effective as ERT in decreasing the cardiovascular risk in postmenopausal women. 8 The beneficial effects of HRT on the cardiovascular system cannot be fully explained by the effects on the lipid profile. 9,10 Therefore, other factors may play a role. Because menopause is associated with an increase in both office and 24-h ambulatory blood pressures, 11 blood pressure elevation may be also a factor contributing to the elevated cardiovascular risk in postmenopausal women, and the beneficial effects of HRT on the cardiovascular risk may be related, in part, to blood pressure lowering. Previous prospective studies in normotensive and hypertensive postmenopausal women 12,13 have not shown any effects of HRT on blood pressure. However, these studies used office blood pressure measurements, which are not very accurate. A more accurate technique for blood pressure determination, 24-h ambulatory blood pressure monitoring (ABPM), did not show blood pressure changes during oral treatment with conjugated estrogens and dydrogesterone in a nonrandomized study of otherwise healthy postmenopausal women or in postmenopausal women with established cardiovascular disease. 14,15 Therefore, we performed a prospective, randomized, open study of the effect of 17 estradiol in combination with dydrogesterone on blood pressures determined with ABPM in healthy, normotensive postmenopausal women. METHODS Postmenopausal, nonhysterectomized women without a history of cardiovascular disease were asked to participate in the study through an advertisement in a newspaper. The first 30 consecutive, healthy postmenopausal women (absence of menstrual blood loss during 6 months and a plasma level of follicle stimulating hormone (FSH) above 21 U/L) without a history of hypertension and with an office blood pressure 170/105 mm Hg were entered into the study within 3 months. Prior use of estrogens, progestagens, or androgens was not allowed. Further exclusion criteria were presence of acute or chronic liver disease, active deep venous thrombosis or cerebral vascular accident, cardiac failure or manifest coronary heart disease, presence of premalignant or malignant disease, abnormal mammogram at screening, abnormal serum thyroid stimulating hormone level, and known diabetes mellitus. Women were randomized to two groups: 15 women were included in the treatment group (HRT group) and 15 women in the control group. During the study three women withdrew: two from the control group because of estrogen use for climacterial complaints (N 1, at 11 months of follow-up) and lack of motivation to participate (N 1, at 10 months of follow-up), and one from the HRT group (lack of compliance at 6 weeks after the start of treatment period). As this last woman did not continue the HRT schedule, she was removed from the analysis. Thus, data for 29 women (14 in HRT group, 15 in the control group) were analyzed. All women in the HRT group took part in a double-blind, randomized multicenter trial to investigate the efficacy and safety of dydrogesterone in endometrial protection during continuous 17 -estradiol replacement, and were randomized to treatment with either 5 or 10 mg dydrogesterone. Thus, this treatment group received therapy consisting of 28-day cycles: 1 mg of micronized 17 -estradiol (Zumenon, Solvay Duphar B.V., Weesp, The Netherlands) in an open fashion once daily, and 5 or 10 mg (N 7 each) dydrogesterone (Duphaston, Solvay Duphar B.V.) once daily during the last 14 days of each 28-day treatment cycle in a blinded fashion. Women in the control group did not receive any treatment. Follow-up was 1 year. The protocol was approved by the Institutional Review Board and all women gave written informed consent. Ambulatory Blood Pressure Monitoring ABPM was performed with a SpaceLabs monitor (SpaceLabs Inc., Redmond, WA) in 30 women at baseline, in 29 women at 3 months, and in 27 women at 12 months of follow-up between the eighth and twelfth day of the 28-day treatment cycle. At the start of each ABPM registration three measurements were taken with the SpaceLabs monitor in the outpatient clinic. Means of these three blood pressure readings were considered as office blood pressures. Thereafter, blood pressure readings were taken at 15-min intervals from 7:00 am to 10:00 pm and at 20-min intervals from 10:00 pm to 7:00 am. Results of blood pressure measurements were not displayed by the monitor. Mean systolic and diastolic blood pressure values of the waking and sleeping periods were calculated as means of hourly averages. The waking and the sleeping periods were taken from the patients diaries. Other Data Hemoglobin and creatinine were determined with routine laboratory methods; FSH with a chemiluminescence-enhanced immunoassay (Amerlite Technique, Amersham Amerlite Analyser, Amersham Radiochemical, Amersham, Buckinghamshire, England). Body mass index (BMI) was calculated as body weight (kg) divided by height squared (m 2 ). Statistics Comparisons of means of the two groups were performed with nonpaired Student t tests; comparison of duration of amenorrhea was made with a Wilcoxon test. Effects of therapy over time were studied with analysis of variance (ANOVA) for repeated
3 AJH OCTOBER 1998 VOL. 11, NO. 10, PART 1 ABPM DECLINES DURING POSTMENOPAUSAL HRT 1149 TABLE 1. BASELINE CHARACTERISTICS OF THE CONTROL GROUP AND THE STUDY GROUP Control Group Study Group Number Age (years) 53.1 (3.4) 51.4 (4.0).2 Body mass index (kg/m 2 ) 25.6 (4.2) 25.1 (3.7).8 Hemoglobin (mmol/l) 8.2 (0.5) 8.0 (0.5).2 Serum creatinine ( mol/l) 81.7 (9.7) 81.2 (7.8).9 Duration of amenorrhea (months): median range RRsys office (mm Hg) (13.0) (9.0).2 RRdia office (mm Hg) 77.0 (10.2) 80.2 (8.4).4 RRsys 24-h (mm Hg) (11.2) (9.2).4 RRdia 24-h (mm Hg) 71.3 (7.4) 74.4 (6.6).3 Means (SD) unless otherwise indicated. Results of baseline ambulatory blood pressures were obtained in 13 women from the control group and in 14 women from the study group. RRsys, blood pressure systolic; RRdia, blood pressure diastolic; office, office measurement; 24 h, mean 24-h ambulatory blood pressure measurement value. P measurements. In the event of incomplete blood pressure data sets, ANOVA was performed both without the cases with incomplete data sets and with all cases replacing the missing value by its previous one. Linear regression analysis was performed to evaluate the effect of the body mass index (BMI) on the change of the blood pressures in the control group, using the change in systolic or diastolic 24-h ABPM value as the dependent, and the change in BMI as the independent variable. All testing was two-sided; P.05 was considered statistically significant. All tests were performed with the Statistical Package of Social Sciences (SPSS) software package. RESULTS The groups were well matched (Table 1). Successful 24-h ambulatory blood pressure measurements could be obtained in 13 women from the control group and 14 women from the study group at baseline. Baseline characteristics were not different between the two dydrogesterone subgroups (data not shown). Body mass index did not change during the study period in the HRT group (from 25.0 [3.8] to 25.3 [4.2] kg/m 2 at 12 months, P.2), whereas there was a small but significant increase in the control group (from 25.3 [4.7] to 25.8 [4.7] kg/m 2 at 12 months, P.001). Hemoglobin concentrations did not change in either group. Both office and 24-h ambulatory blood pressures were not significantly different between the control group and the HRT group at baseline (Table 1), or at 3 or 12 months of follow-up. Consistent changes of office blood pressures during the study period were not observed and these changes did not differ significantly between the groups (Table 2, Figure 1). Ambulatory pressures, however, increased significantly in the control group at 3 months of follow-up and showed a consistent and significant decline in the HRT group at 12 months (Table 2, Figure 2). ANOVA for repeated measurements (performed in 13 women from the HRT group and 11 from the control group because of four incomplete blood pressure data sets) did not reveal significant changes of office blood pressure over time or differences between the groups. Analysis of blood pressures obtained with ABPM indicated that both systolic and diastolic blood pressures declined significantly in the HRT group (from [9.2]/74.4 (6.6) mm Hg to [7.9]/70.5 TABLE 2. CHANGES FROM BASELINE OF OFFICE BLOOD PRESSURES AND 24-h AMBULATORY BLOOD PRESSURES IN THE HRT AND CONTROL GROUPS AT 3 AND 12 MONTHS OF FOLLOW-UP Control Group Study Group Three months RRsys office (mm Hg) 1.0 ( 7.3 to 5.3) 5.2 ( 10.1 to 0.2)* RRdia office (mm Hg) 2.5 ( 7.8 to 2.8) 1.9 ( 5.0 to 1.1) RRsys 24-h (mm Hg) 4.5 (0.9 to 8.0)* 2.8 ( 5.8 to 0.2) RRdia 24-h (mm Hg) 4.1 (1.6 to 3.6)* 2.3 ( 4.3 to 0.4)* Twelve months RRsys office (mm Hg) 4.5 (0.6 to 8.4)* 2.4 ( 10.7 to 5.9) RRdia office (mm Hg) 0.2 ( 5.5 to 5.2) 3.3 ( 8.3 to 1.7) RRsys 24-h (mm Hg) 3.3 ( 0.9 to 7.4) 5.5 ( 2.2 to 0.9)* RRdia 24-h (mm Hg) 1.7 ( 1.8 to 5.1) 4.2 ( 6.7 to 1.8)* Means (95% CI). * P.05 versus baseline. RRsys, change in systolic blood pressure; RRdia, change in diastolic blood pressure; 95% CI, 95% confidence interval; 24 h, mean 24-h ambulatory blood pressure measurement value.
4 1150 VAN ITTERSUM ET AL AJH OCTOBER 1998 VOL. 11, NO. 10, PART 1 FIGURE 1. Changes in systolic and diastolic office blood pressures from baseline after 3 and 12 months of follow-up in the control group (filled circles) and the HRT group (open circles). Horizontal lines represent means; P values are taken from nonpaired Student t test); P (ANOVA) systolic/diastolic.3/.2 for the HRT group, and.1/.5 for the control group (N 11 for the control group, N 13 for the HRT group). [5.7] after 1 year of treatment, P [ANOVA].005/.003). In the control group there was an increase in ABPM values during the study period (from [11.2]/71.3 [7.4] to [10.1]/72.5 [7.2] after 1 year, P [ANOVA].054/.02). The interaction between therapy and time for ambulatory blood pressures was significant P [ANOVA].001 and.0001 for 24-h systolic and 24-h diastolic blood pressures, respectively, indicating that blood pressure changes over time differed significantly between the HRT and the control groups. Analysis of ABPM-values during the waking and the sleeping periods revealed similar results to the analysis of 24-h mean values (data not shown). Changes in blood pressures over time did not differ between the two dydrogesterone subgroups (P FIGURE 2. Changes in systolic and diastolic 24-h ambulatory blood pressures from baseline at 3 and 12 months of follow-up in the control group (filled circles) and in the HRT group (open circles). Horizontal lines represent means; P-values are taken from nonpaired Student t test); P (ANOVA) systolic/diastolic.005/.003 for the HRT group,.054/.02 for the control group (N 11 for the control group, N 13 for the HRT group). [ANOVA].77). When the missing values were replaced by the previous ones in time, the ANOVA analysis yielded similar results (data not shown). Results of the linear regression analysis, which was performed to study the relationship between BMI and blood pressure in the control group, showed that the increase in blood pressure could not be attributed to the increase in BMI ( 5.6, P.3 for systolic changes, and 4.9, P.3 for diastolic changes). DISCUSSION Menopause is associated with a large increase in the risk of cardiovascular diseases and an increase in blood pressure, although the latter issue is somewhat controversial. 1,11,16 We performed a prospective, ran-
5 AJH OCTOBER 1998 VOL. 11, NO. 10, PART 1 ABPM DECLINES DURING POSTMENOPAUSAL HRT 1151 domized study on the effects of HRT on blood pressure in 29 postmenopausal women. After randomization, the treatment and the control groups did not differ significantly with respect to age, BMI, serum creatinine, hemoglobin level, duration of amenorrhea, and blood pressures. During the study, some changes in office blood pressures were observed, but a steady change did not occur. These results are in concordance with those of the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, which found slight decreases in systolic (office) blood pressures during the first year of treatment that were not statistically significant. 12 However, in the present study, ABPM, a more accurate technique for blood pressure determination, was used as well. ABPM results did not differ significantly between the HRT and the control groups at baseline. In the control group, ambulatory blood pressures increased at 3 and 12 months of follow-up. This increase in blood pressures could not be explained by the (small) increase in BMI. In the HRT group, an ongoing decrease in blood pressures was observed at 3 and 12 months. ANOVA for repeated measurements confirmed the conclusion that time effects differed between the two groups. Blood pressure changes in the HRT group were not attributable to a decline in hemoglobin concentration (due to uterine withdrawal bleeding) or changes in BMI. The initial rise of ABPM values in the control group and the initial decline in the HRT group might partially be due to regression to the mean; the results of the unpaired Student t test (P.002), however, indicate that the chance that this explanation is true is 0.2%. In addition, regression to the mean is an extremely unlikely explanation for the further decline in blood pressures in the HRT group at 12 months. The reason why ABPM detects small blood pressure changes during HRT, whereas office measurements fail to demonstrate these effects, might at least partially be the greater number of blood pressure measurements, which provides more accurate estimates of the blood pressure. In the present study, this is illustrated by the variances of changes in office pressure, which are comparable with the results of the PEPItrial, 12 but which were 1.5 to 2 times higher than the variances of changes of the ABPM registrations (as reflected by the confidence intervals in Table 2). The results of the office blood pressure changes during HRT in the present study are in concordance with the results of the PEPI trial, suggesting that effects on blood pressure are comparable in both studies. However, in the present study, ABPM in the HRT group showed a significant decline in blood pressures of 5.5/4.2 mm Hg. Changes in blood pressures during the waking and sleeping periods were similar. To detect declines of 4 to 5 mm Hg in blood pressure with a power of 90%, the PEPI trial would have needed 200 patients/group, whereas the groups consisted of only 175 patients. Therefore, the absence of significant changes in blood pressures in this trial could be explained by a lack of statistical power. Different effects of ERT or HRT on blood pressure may be due to the composition of the pharmacotherapeutical agent or the route of its administration. A previous observational study showed a blood pressure decline, determined with ABPM, during transdermal ERT, not with oral ERT. 14 The compound used in the present study, 17 -estradiol, seems to have vasodilating and blood pressure-lowering properties The mechanism of this vasodilation and blood pressure lowering is not fully understood. Potential mechanisms are the increase of the activity of PGI 2 (a vasodilating prostaglandin) and nitric oxide, and the observed decreases in plasma endothelin and renin levels during ERT Determination of these mechanisms was not within the scope of the present study. Our data raise the possibility that subtle blood pressure changes may at least be partially responsible for the unexplained part of the decline in cardiovascular risk with HRT. If confirmed by other studies, the findings of the present study may be relevant for clinical practice. Although it has been shown that HRT does not induce an elevation of blood pressure in hypertensive postmenopausal women, 13 in clinical practice HRT has often been withheld from hypertensive patients. If the blood pressure lowering effects of HRT can be confirmed in larger studies and in hypertensive postmenopausal women, HRT should be considered as initial therapy for the increased cardiovascular risk in these patients. Some issues remain to be elucidated. In the PEPI trial a (nonsignificant) increase in blood pressure was observed in the second year of HRT. 12 Another study in hypertensive postmenopausal women did not observe an ongoing increase after 1 year of HRT: even after 3 years of HRT, office blood pressures were not different from baseline. 13 Therefore, further studies should be performed to confirm the observation of the present study that ambulatory blood pressures fall during the first year of HRT. Additionally they should explore ambulatory blood pressures after 1 year of HRT. In conclusion, ambulatory not office blood pressures decline during hormone replacement therapy (micronized 17 -estradiol and dydrogesterone) in postmenopausal women. Larger studies using ABPM for determination of blood pressures are needed to confirm these results and to explore the course of ambulatory blood pressures after 1 year of HRT.
6 1152 VAN ITTERSUM ET AL AJH OCTOBER 1998 VOL. 11, NO. 10, PART 1 REFERENCES 1. Kannel WB, Wilson PW: Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 1995;155: Stampfer MJ, Colditz GA: Estrogen replacement and coronary heart disease: a quantative assessment of the epidemiologic evidence. Prevent Med 1991;20: Grady D, Rubin SM, Petitti DB, et al: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117: Stevenson JC, Crook D, Godsland IF, et al: Hormone replacement therapy and the cardiovascular system. Nonlipid effects. Drugs 1994;47(suppl)2: Pines A, Mijatovic V, van der Mooren MJ, et al: Hormone replacement therapy and cardioprotection: basic concepts and clinical considerations. Eur J Obstet Gynaecol Reprod Biol 1997;71: Mijatovic V, Pines A, Stehouwer CDA, et al: The effects of oestrogens on vessel wall and cardiac function, haemostasis and homocysteine metabolism. Eur J Menopause 1996;3: Kon Koh K, Mincemoyer R, Bui MN, et al: Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997;336: Grodstein F, Stampfer MJ, Manson JE, et al: Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335: Barrett-Connor E, Bush TL: Estrogen and coronary heart disease in women. JAMA 1991;265: Bush TL, Barrett-Connor E, Cowan LD, et al: Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75: Staessen J, Bulpitt CJ, Fagard R, et al: The influence of menopause on blood pressure. J Hum Hypertens 1989; 3: The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273: Lip GYH, Beevers M, Churchill D, et al: Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens 1994;8: Akkad AA, Halligan AW, Abrams K, et al: Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy. Obstet Gynecol 1997;89: Pripp UM, Hall G, Landgren BM, et al: The influence of long-term HRT treatment on ambulatory blood pressure in older women with coronary artery disease (Abst. F178). 8th International Congress on the Menopause, Sydney, Australia, November 3 7, Casiglia E, D Este D, Ginocchio G, et al: Lack of influence of menopause on blood pressure and cardiovascular risk profile: a 16 year longitudinal study concerning a cohort of 568 women. J Hypertens 1996;14: Volterrani M, Rosano G, Coats A, et al: Estrogen acutely increases peripheral blood flow in postmenopausal women. Am J Med 1995;99: Riedel M, Oeltermann A, Mugge A, et al: Vascular responses to 17 beta-oestradiol in postmenopausal women. Eur J Clin Invest 1995;25: Luotola H: Blood pressure and hemodynamics in postmenopausal women during estradiol-17 beta substitution. Ann Clin Res 1983;15(suppl 38): Polderman KH, Stehouwer CDA, van der Kamp GJ, et al: Influence of sex hormones on plasma levels of endothelin. Ann Intern Med 1993;118: Schwartz J, Freeman R, Frishman W: Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women. J Clin Pharmacol 1995;35: Schunkert H, Danser AH, Hense HW, et al: Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997;95:
Postmenopausal hormone therapy and cancer risk
International Congress Series 1279 (2005) 133 140 www.ics-elsevier.com Postmenopausal hormone therapy and cancer risk P. Kenemans*, R.A. Verstraeten, R.H.M. Verheijen Department of Obstetrics and Gynaecology,
More informationArterial blood pressure (BP) increases with
AJH 1998;11:909 913 ORIGINAL CONTRIBUTIONS Estradiol-17 Reduces Blood Pressure and Restores the Normal Amplitude of the Circadian Blood Pressure Rhythm in Postmenopausal Hypertension Giuseppe Mercuro,
More informationEffects of Hormone Therapy on Serum Lipid Levels in Postmenopausal Korean Women
J MM pissn: 2288-6478, eissn: 2288-6761 Journal of Menopausal Medicine 2015;21:104-111 Original Article Effects of Hormone Therapy on Serum Lipid Levels in Postmenopausal Korean Women Jee-Yeon Lee, Hye
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationProspective, randomized, controlled study of the effect of hormone replacement therapy on peripheral blood flow velocity in postmenopausal women
FERTILITY AND STERILITY VOL. 70, NO. 2, AUGUST 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Prospective, randomized,
More informationPostmenopausal hormones and coronary artery disease: potential benefits and risks
CLIMACTERIC 2007;10(Suppl 2):21 26 Postmenopausal hormones and coronary artery disease: potential benefits and risks R. A. Department of Obstetrics and Gynecology, Columbia University, New York, New York,
More informationHaemostasis, thrombosis risk and hormone replacement therapy
Haemostasis, thrombosis risk and hormone replacement therapy Serge Motte Brussels 13.05.17 - MY TALK TODAY The coagulation cascade and its regulation Effects of hormone replacement therapy on haemostasis
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Predicting the menopause The menopause marks the end of ovarian follicular activity and is said to have occurred after 12 months amenorrhoea. The average age of the menopause is between 45 and 60 years
More informationPremenopausal women have a lower incidence of cardiovascular
Estradiol With or Without Progesterone and Ambulatory Blood Pressure in Postmenopausal Women Ellen W. Seely, Brian W. Walsh, Marie D. Gerhard, Gordon H. Williams Abstract The purpose of this study was
More informationAppendix: Reference Table of HT Brand Names
Appendix: Reference Table of HT Brand Names This is a full reference table in alphabetical order, of Brand Name drugs used in HT. It is the basis for prescription advice throughout this handbook. Drug
More informationLow & Ultra Low Dose HRT The Cardiovascular Impact
Low & Ultra Low Dose HRT The Cardiovascular Impact Wyeth Symposium, Turin 29 th Sept 2007 Nick Panay Consultant Gynaecologist Queen Charlotte s & Chelsea and Chelsea & Westminster Hospitals Honorary Senior
More informationBRIEF COMMUNICATIONS. KEY WORDS: Ambulatory blood pressure monitoring, placebo effect, antihypertensive drug trials.
AJH 1995; 8:311-315 BRIEF COMMUNICATIONS Lack of Placebo Effect on Ambulatory Blood Pressure Giuseppe Mancia, Stefano Omboni, Gianfranco Parati, Antonella Ravogli, Alessandra Villani, and Alberto Zanchetti
More informationCurrent Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes
Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes The Northern California Kaiser Permanente Diabetes Registry, 1995 1998
More informationPostmenopausal hormone therapy - cardiac disease risks and benefits
Postmenopausal hormone therapy - cardiac disease risks and benefits Tomi S. Mikkola, MD Helsinki University Central Hospital Department of Obstetrics and Gynecology Helsinki, Finland Disclosures Speaker/consulting
More informationThe role of physical activity in the prevention and management of hypertension and obesity
The 1 st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) Berlin, October 26-29 2005 The role of physical activity in the prevention and management of hypertension and obesity
More informationFor more than 50 million American women, and millions
AHA Science Advisory Hormone Replacement Therapy and Cardiovascular Disease A Statement for Healthcare Professionals From the American Heart Association Lori Mosca, MD, PhD; Peter Collins, MD; David M.
More informationHow well do office and exercise blood pressures predict sustained hypertension? A Dundee Step Test Study
(2000) 14, 429 433 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE How well do office and exercise blood pressures predict sustained hypertension?
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationFinancial Conflicts of Interest
Hormone Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us)? S. Mitchell Harman, M.D., Ph.D. Chief, Endocrine Division Phoenix VA Health Care System Clinical Professor, Medicine
More informationOverview of the outcome trials in older patients with isolated systolic hypertension
Journal of Human Hypertension (1999) 13, 859 863 1999 Stockton Press. All rights reserved 0950-9240/99 $15.00 http://www.stockton-press.co.uk/jhh Overview of the outcome trials in older patients with isolated
More informationDepartment of Obstetrics and Gynecology, Osaka Medical College, Takatsuki-city, Osaka , Japan. Pituitary gonadotropin, Clinical managament
Original Article Adequate Reduction Degree of Pituitary Gonadotropin Level in the Clinical Management of Short-Term Hormone Replacement Therapy of Women with Menopausal Symptoms Department of Obstetrics
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationFERTILITY AND STERILITY
MENOPAUSE FERTILITY AND STERILITY VOL. 82, NO. 6, DECEMBER 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. HMR 3339, a novel
More informationHKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 Revised November BENEFITS OF HRT
HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 Revised November 2006 Published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College
More informationCoronary Heart Disease in Women Go Red for Women
Coronary Heart Disease in Women Go Red for Women Dr Fiona Stewart Green Lane Cardiovascular Service and National Women s Health Auckland City Hospital Auckland Heart Group Women are Different from Men
More informationHigh-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension
(2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers
More informationWEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital
WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationEffects of exercise, diet and their combination on blood pressure
(2005) 19, S20 S24 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Effects of exercise, diet and their combination on blood pressure Department
More informationAusPharm CE Hormone therapy 23/09/10. Hormone therapy
Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationDate: 24 April-2007 Trial ID: GHTUR/E/2 Version: 2 Integrated Clinical Trial Report Status: Final ICTR Synopsis Page: 1 of 5
ICTR Synopsis Page: 1 of 5 Synopsis TITLE OF TRIAL INDUCTION OF PUBERTY WITH 17 Β-ESTRADIOL IN GIRLS WITH TURNER SYNDROME. AN OPEN RANDOMISED TRIAL TRIAL CODE: GHTUR/E/2 INVESTIGATORS IN TOTAL, 35 PRINCIPAL
More informationEstrogen and progestogen therapy in postmenopausal women
Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone
More informationNatural Hormones Replacement An Evidence and Practice Based Approach
Natural Hormones Replacement An Evidence and Practice Based Approach Andres Ruiz, PharmD, MSc, FACA President/Partner Stonegate Pharmacy PRESENTED BY THE AMERICAN COLLEGE OF APOTHECARIES 2830 SUMMER OAKS
More informationAmerican Journal of Internal Medicine
American Journal of Internal Medicine 2016; 4(3): 49-59 http://www.sciencepublishinggroup.com/j/ajim doi: 10.11648/j.ajim.20160403.12 ISSN: 2330-4316 (Print); ISSN: 2330-4324 (Online) The Effect of Dose-Reduced
More informationLipid Profile and Menopausal Status * Fouad Hamad Al - Dahhan FRCOG # Lamia M. Al - Naama Ph.D Med. Bioch. UK *Ahlam Disher CAB Gyn & Ob
Lipid Profile and Menopausal Status * Fouad Hamad Al - Dahhan FRCOG # Lamia M. Al - Naama Ph.D Med. Bioch. UK *Ahlam Disher CAB Gyn & Ob Abstract Background: Dyslipidemia is a major cause of cardiovascular
More informationHormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health
More information25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?
Research Subcutaneous estrogen replacement therapy. Jones SC. Journal of Reproductive Medicine March, 2004; 49(3):139-142. Department of Obstetrics and Gynecology, Keesler Medical Center, Keesler Air Force
More informationUniversity of Padova, Padua, Italy, and HARVEST Study Group, Italy
University of Padova, Padua, Italy, and HARVEST Study Group, Italy ISOLATED SYSTOLIC HYPERTENSION IN THE YOUNG DOES NOT IMPLY AN INCREASED RISK OF FUTURE HYPERTENSION NEEDING TREATMENT Mos L, Saladini
More informationΥπέρταση στις γυναίκες
Υπέρταση στις γυναίκες Ελένη Τριανταφυλλίδη Διευθύντρια ΕΣΥ Καρδιολογίας Υπεύθυνη Αντιυπερτασικού Ιατρείου Β Πανεπιστημιακή Καρδιολογική Κλινική Νοσοκομείο ΑΤΤΙΚΟΝ Cardiovascular disease is the Europe
More informationAmerican Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease
American Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease AMWA is a leader in its dedication to educating all physicians and their patients about heart disease,
More informationNormal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis
CLINICAL RESEARCH STUDY Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis Gregory A. Nichols, PhD, Teresa A. Hillier, MD, MS, Jonathan B. Brown, PhD, MPP Center for Health Research, Kaiser
More informationMenopause and HRT. John Smiddy and Alistair Ledsam
Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation
More informationHormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare
Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest
More informationComparison of arbitrary definitions of circadian time periods with those determined by wrist actigraphy in analysis of ABPM data
Journal of Human Hypertension (1999) 13, 449 453 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE Comparison of arbitrary definitions of
More informationNoha H. Farag, M.D., Bruce A. Barshop, M.D., Ph.D., and Paul J. Mills, Ph.D.
MENOPAUSE FERTILITY AND STERILITY VOL. 79, NO. 2, FEBRUARY 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effects
More informationWHI, HERS y otros estudios: Su significado en la clinica diária. Manuel Neves-e-Castro
WHI, HERS y otros estudios: Su significado en la clinica diária III Congreso Ecuatoriano de Climaterio Menopausia y Osteoporosis por Manuel Neves-e-Castro (Lisboa-Portugal) Julho, 2003 Machala The published
More informationHORMONE REPLACEMENT THERAPY-UPDATE KHALED SAKHEL, MD FACOG FACS FAIUM ASSOCIATE PROFESSOR EASTERN VIRGINIA MEDICAL SCHOOL
HORMONE REPLACEMENT THERAPY-UPDATE KHALED SAKHEL, MD FACOG FACS FAIUM ASSOCIATE PROFESSOR EASTERN VIRGINIA MEDICAL SCHOOL INTRODUCTION NORMAL WOMEN HAVE MENOPAUSE AT A MEAN AGE OF 51 YEARS, WITH 95 PERCENT
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1997, by the Massachusetts Medical Society VOLUME 336 J UNE 19, 1997 NUMBER 25 POSTMENOPAUSAL HORMONE THERAPY AND MORTALITY FRANCINE GRODSTEIN, SC.D., MEIR
More informationP remenopausal women have a lower risk of coronary
777 CARDIOVASCULAR MEDICINE Acute and chronic effects of oestradiol on left ventricular diastolic function in hypertensive postmenopausal women with left ventricular diastolic dysfunction I N Alecrin,
More informationPERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.
PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationCARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES
CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis
More informationEffects of the Transition from Premenopause to Postmenopause on Lipids and Lipoproteins: Quantification and Related Parameters
ORIGINAL ARTICLE DOI: 10.3904/kjim.2011.26.1.47 Effects of the Transition from Premenopause to Postmenopause on Lipids and Lipoproteins: Quantification and Related Parameters Eun Jeung Cho 1, Yun Joo Min
More informationINTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE
Anand IS,, 2014; Volume 3(3): 178-187 INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE EFFECT OF NEBIVOLOL AND METOPROLOL ON PLATELET ACTIVATION IN HYPERTENSIVE PATIENTS ANAND IS, PATEL
More informationSUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics
Supplementary Table 1. Baseline Patient Characteristics Normally distributed data are presented as mean (±SD), data that were not of a normal distribution are presented as median (ICR). The baseline characteristics
More informationORIGINAL INVESTIGATION. Hormone Replacement Therapy and Associated Risk of Stroke in Postmenopausal Women
ORIGINAL INVESTIGATION Hormone Replacement Therapy and Associated Risk of Stroke in Postmenopausal Women Rozenn N. Lemaitre, PhD, MPH; Susan R. Heckbert, MD, PhD; Bruce M. Psaty, MD, PhD; Nicholas L. Smith,
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationDoes Black Cohosh Improve Anxiety/Depression Symptoms in Women Who Are Postmenopausal?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Does Black Cohosh Improve Anxiety/Depression
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationThe effects of soy protein in women and men with elevated plasma lipids 1
BioFactors 12 (2000) 251 257 251 IOS Press Original report The effects of soy protein in women and men with elevated plasma lipids 1 R. Mackey a, A. Ekangaki a and J.A. Eden b, a Sydney Menopause Centre,
More informationConflict of Interest. Problems in Peri- Postmenopausal Women. Management of Menopause 10/24/2014. Financial conflict none Research conflict
Conflict of Interest Management of Menopause Marcelle I. Cedars, M.D. Professor and Director Division of Reproductive Endocrinology and Infertility UCSF Financial conflict none Research conflict Funded
More informationConflict of Interest. Problems in Peri- Postmenopausal Women. Hormone Replacement Therapy Where are we in /27/2011
Hormone Replacement Therapy Where are we in 2011 Conflict of Interest Financial conflict none Research conflict Funded research: Kronos Early Estrogen Progestin Study (KEEPS) Marcelle I. Cedars, M.D. Professor
More informationBrain tissue and white matter lesion volume analysis in diabetes mellitus type 2
Brain tissue and white matter lesion volume analysis in diabetes mellitus type 2 C. Jongen J. van der Grond L.J. Kappelle G.J. Biessels M.A. Viergever J.P.W. Pluim On behalf of the Utrecht Diabetic Encephalopathy
More informationESTRADIOL LEVELS AND SERUM LIPIDS
ESTRADIOL LEVELS AND SERUM LIPIDS Frank Z. Stanczyk et al. American Journal of OB/GYN, Volume 159, No. 6 A Randomized Comparison of Non Oral Estradiol Delivery in Post-Menopausal Women. Pellets produce
More informationPractical aspects of preventing and managing atherosclerotic disease in post-menopausal women
European Heart Journal (1996) 17 {Supplement D), 32-37 Practical aspects of preventing and managing atherosclerotic disease in post-menopausal women J. M. Sullivan University of Tennessee, Memphis, TN,
More informationEvidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy
European Heart Journal (1996) 17 {Supplement D), 9-14 Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy T. L. Bush The increasing use
More informationPremature Menopause : Diagnosis and Management
Guideline Number 3 : August 2010 Premature Menopause : Diagnosis and Management Introduction : Premature menopause is a serious condition that affects young women and remains an enigma. The challenges
More informationHKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 revised January 2003
HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 revised January 2003 published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College
More informationcoronary heart disease (CHD) is the leading
Appendix I: Evidence on HRT and Coronary Heart Disease I coronary heart disease (CHD) is the leading cause of death among U.S. women, surpassing the rates from cancer and other diseases (13). Any change
More informationA study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study
BJOG: an International Journal of Obstetrics and Gynaecology September 2002, Vol. 109, pp. 1056 1062 A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth
More informationStopping oral contraceptives: an effective blood pressure-lowering intervention in women with hypertension
(2005) 19, 451 455 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Stopping oral contraceptives: an effective blood pressure-lowering intervention
More informationHormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study
European Journal of Endocrinology (2006) 154 101 107 ISSN 0804-4643 CLINICAL STUDY Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention
More informationDiabetes, Diet and SMI: How can we make a difference?
Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative
More informationANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION*
Progress in Clinical Medicine 1 ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION* Keishi ABE** Asian Med. J. 44(2): 83 90, 2001 Abstract: J-MUBA was a large-scale clinical
More informationControversies in Primary Care Pros and Cons of HRT on patients with CHD
Controversies in Primary Care Pros and Cons of HRT on patients with CHD Claire Bellone MSc Clinical Nurse Specialist Menopause Nottingham Declaration Honorariums & Sponsorship from Bayer, Novonortis, Wyeth
More informationAppendix H: Evidence on HRT and Gallbladder Disease H
Appendix H: Evidence on HRT and Gallbladder Disease H T here are several theoretical reasons to expect a causal link between estrogens and gallbladder disease. In particular, estrogens increase the risk
More informationORIGINAL ARTICLE AMBULATORY BLOOD PRESSURE IN OBESITY. Introduction. Patients and Methods
Vol. 2, Issue 1, pages 31-36 ORIGINAL ARTICLE AMBULATORY BLOOD PRESSURE IN OBESITY By Alejandro de la Sierra, MD Luis M. Ruilope, MD Hypertension Units, Hospital Clinico, Barcelona & Hospital 12 de Octubre,
More informationChapter-IV. Blood pressure and heart rate variability as function of ovarian cycle in young women
Blood pressure and heart rate variability as function of ovarian cycle in young women INTRODUCTION In human females, the menstrual cycle begins with the onset of menstrual flow on day 1. The menstrual
More informationSee page 138 OBJECTIVES BACKGROUND METHODS RESULTS CONCLUSIONS
Journal of the American College of Cardiology Vol. 34, No. 1, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00155-2 Hormone
More informationOrals,Transdermals, and Other Estrogens in the Perimenopause
Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter
More informationEstetrol, the Next Generation of Hormone Therapy: Results of a Phase 2b Dose-finding Study in Postmenopausal Women (E4 Relief)
Estetrol, the Next Generation of Hormone Therapy: Results of a Phase 2b Dose-finding Study in Postmenopausal Women (E4 Relief) Prof Wulf H Utian Case Western Reserve University School of Medicine, Cleveland,
More informationCLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN
CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN Nanette K. Wenger, MD, is a recognized authority on women and coronary heart disease. She chaired the US National Heart, Lung, and Blood Institute conference
More informationHypertension is a common medical disorder, affecting. Is Resistant Hypertension Really Resistant? Mark A. Brown, Megan L. Buddle, and Allison Martin
AJH 2001; 14:1263 1269 Is Resistant Hypertension Really Resistant? Mark A. Brown, Megan L. Buddle, and Allison Martin Background: Managing resistant hypertension is difficult and mostly involves expensive
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationCoronary heart disease risk factors and menopause: a study in 1684 French women
Atherosclerosis 142 (1999) 415423 Coronary heart disease risk factors and menopause: a study in 1684 French women Florence A. Trémollières *, Jean-Michel Pouilles, Colette Cauneille, Claude Ribot Menopause
More informationCURRENT HORMONAL CONTRACEPTION - LIMITATIONS
CURRENT HORMONAL CONTRACEPTION - LIMITATIONS Oral Contraceptives - Features MERITS Up to 99.9% efficacy if used correctly and consistently Reversible method rapid return of fertility Offer non-contraceptive
More informationBaldness and Coronary Heart Disease Rates in Men from the Framingham Study
A BRIEF ORIGINAL CONTRIBUTION Baldness and Coronary Heart Disease Rates in Men from the Framingham Study The authors assessed the relation between the extent and progression of baldness and coronary heart
More informationWomen and Heart Disease
Women and Heart Disease The Very Latest in Cardiovascular Medicine and Surgery Gretchen L. Wells, MD, PhD, FACC Thomas Whayne Endowed Professor in Women s Heart Health Gill Heart Institute University of
More informationSupplementary Online Content
Supplementary Online Content Gartlehner G, Patel SV, Feltner C, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for
More informationProblems in Postmenopausal Women
Menopausal Management: Where are we in 27? Marcelle I. Cedars, M.D. Professor and Director Division of Reproductive Endocrinology and Infertility UCSF Problems in Postmenopausal Women Vasomotor symptoms
More informationDoes Hysterectomy Lead to Weight Gain or Does Overweight Lead to Hysterectomy?
Dr Janneke BERECKI D Fitzgerald, J Berecki, R Hockey and A Dobson 1 1 School of Population Health, Faculty of Health Sciences, University of Queensland, Herston, QLD, Australia Does Hysterectomy Lead to
More informationCardiovascular Disease in Women -Vive La Difference? Dr Homeyra Douglas Consultant Cardiologist Aintree University Hospital
Cardiovascular Disease in Women -Vive La Difference? Dr Homeyra Douglas Consultant Cardiologist Aintree University Hospital Death By Cause - Women 2004 UK Death by Cause-Women 2004 UK -CVD is responsible
More information& Wilkins. a Division of Cardiology, Schulich Heart Centre, b Institute for Clinical and
Original article 333 Optimum frequency of office blood pressure measurement using an automated sphygmomanometer Martin G. Myers a, Miguel Valdivieso a and Alexander Kiss b,c Objective To determine the
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More information